Poop pills plus immunotherapy: new hope for stubborn cancers?

NCT ID NCT05533983

Recruiting now Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a fecal microbiota transplant (FMT) combined with the immunotherapy drug nivolumab can help people with advanced solid cancers that stopped responding to prior treatment. About 50 participants will receive the combination to see if it can shrink tumors. The goal is to find a new way to make immunotherapy work again.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fecal microbiota transplant (FMT) plus nivolumab
What this could lead to: If it works, this could offer a new treatment option for people with advanced solid cancers that no longer respond to standard immunotherapy.
What could go wrong: This is a small, early-phase trial with only 50 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.